Adults with T cell cancers have short survival and lack targeted therapies, making TRBC1 an attractive target. However, early anti-TRBC1 CAR T cell trials had low response rates and challenges.
Here we demonstrate that CAR T cells are lost due to killing by the patient's normal T cells, reducing their efficacy. To circumvent this issue, we developed an antibody-drug conjugate that could kill TRBC1+ cancer cells in vitro and cure human T cell cancers in mouse models.
[
add
]
[
|
|
...
]